• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Ltd ADR (NY: TAK )

    15.04 +0.07 (+0.50%)
    Streaming Delayed Price Updated: 9:46 AM EDT, Aug 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 280,448
    Open 14.87
    Bid (Size) 15.03 (12)
    Ask (Size) 15.04 (16)
    Prev. Close 14.96
    Today's Range 14.87 - 15.04
    52wk Range 12.57 - 16.39
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
    FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
    Via Benzinga
    Exposures Product Safety
    New Study Reveals How Classical Music Could Revolutionize Depression Care
    In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
    Via PressReach
    Exposures Product Safety

    Performance

    YTD
    +4.85%
    +4.85%
    1 Month
    +9.74%
    +9.74%
    3 Month
    +14.68%
    +14.68%
    6 Month
    +1.31%
    +1.31%
    1 Year
    -1.60%
    -1.60%

    More News

    Read More
    Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
    Via Benzinga
    Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
    Via InvestorPlace
    Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    3 Biotech Stocks to Buy on the Dip: July 2024
    Via InvestorPlace
    Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
    Via Benzinga
    Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
    Via Benzinga
    Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
    Via Talk Markets
    Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
    Via Benzinga
    Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Takeda Announces New Assignments of Directors
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
    Via Benzinga
    Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
    Via Benzinga
    Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
    Via Talk Markets
    Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.